- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00974324
Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma (PTCL)
Phase 2 Study of Endostar Combined With CHOP Regimen as the First Line Chemotherapy for Untreated Peripheral T Cell Lymphoma
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Haiyi Guo, MD
- Phone Number: 5008 86(021)64175590
- Email: guohaiyi@csco.org.cn
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Recruiting
- Fudan University Cancer Hospital
-
Contact:
- Haiyi Guo, MD
- Phone Number: 5008 86(021)64175590
- Email: guohaiyi@csco.org.cn
-
Sub-Investigator:
- Haiyi Guo, MD
-
Principal Investigator:
- Junning Cao, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Disease Characteristics:
Diagnosis of peripheral T-cell:
- Any stage disease allowed
- At least 1 objective measurable disease parameter
No anaplastic lymphoma kinase (ALK)-positive T-cell large cell lymphoma
- ALK-negative T-cell large cell lymphoma allowed
No cutaneous T-cell lymphoma
- No sezary syndrome
- No NK/T cell lymphoma
- No history of or current radiographic evidence of CNS metastasis, including previously treated, resected, or asymptomatic brain lesions or leptomeningeal involvement
Patient Characteristics:
Age:
- 18 -75 years
Performance status:
- ECOG 0-2
Life expectancy:
- No less than 12 weeks
Hematopoietic:
- Absolute neutrophil count ≥ 1,500/mm^3
- Hemoglobulin ≥ 80*10^12/L
- Platelet count ≥ 100,000/mm^3
- No evidence of bleeding diathesis or coagulopathy
Hepatic:
- Bilirubin ≤ 1.5 mg/dL
- AST ≤ 2.5 times ULN
- PT, INR, and PTT ≤ 1.5 times normal
Renal:
- Creatinine ≤ 1.5 times normal
Cardiovascular:
- No cerebrovascular accident within the past 6 months
- No myocardial infarction within the past 6 months
- No unstable angina within the past 6 months
- No New York Heart Association class II-IV congestive heart failure
- No uncontrolled hypertension (i.e., systolic blood pressure [BP] > 150 mm Hg or diastolic BP > 100 mm Hg)
- No other clinically significant cardiovascular or peripheral vascular disease
- LVEF is normal
Other:
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No history of active seizures
- No non-healing ulcer (unless involved with lymphoma)
- No active infection requiring parenteral antibiotics
- No known HIV positivity
- No other active malignancy within the past 6 months except carcinoma in situ of the cervix or basal cell carcinoma of the skin
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy was allowed
Surgery:
- More than 4 weeks since prior major invasive surgery or open biopsy
- At least 7 days since prior minor surgery
- No concurrent major surgery
Exclusion Criteria:
- Prior treatment included chemotherapy and radiotherapy
- With the following risk factors: Uncontrolled or severe cardiovascular disease (e.g., myocardial infarction within the past 6 months, congestive heart failure treated with medications, or uncontrolled hypertension)
- Pregnant or nursing
- Other currently active malignancy except nonmelanoma skin cancer
- Uncontrolled or severe bleeding,diarrhea,intestinal obstruction
- Hypersensitivity to albumen
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: treatment
endostar combined with CHOP regimen
|
endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
efficacy include overall response rate, disease free survival and overall survival
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
safety of endostar combined with CHOP
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Junning Cao, MD, member of Fudan University Cancer Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Endostar protein
Other Study ID Numbers
- PTCL0908
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on T Cell Lymphoma
-
University of Alabama at BirminghamTerminatedAnaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T-cell Lymphomas | Adult T-cell Leukemia | Adult T-cell Lymphoma | Peripheral T-cell Lymphoma Unspecified | T/Null Cell Systemic Type | Cutaneous t-Cell Lymphoma With Nodal/Visceral DiseaseUnited States
-
National Cancer Institute (NCI)WithdrawnHepatosplenic T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | Adult T-cell Leukemia/Lymphoma | Extranodal NK-/T-cell Lymphoma, Nasal Type | Monomorphic Epiteliotrophic Intestinal T-cell LymphomaUnited States
-
BeiGeneCompletedCutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditionsChina, Taiwan, Germany, France, Canada, Italy
-
National Cancer Institute (NCI)CompletedPeripheral T-Cell Lymphoma (PTCL) | T-Cell Prolymphocytic Leukemia | Cutaneous T Cell Lymphoma (CTCL) | T-Cell Lymphoma Relapsed | Adult T-Cell Leukemia (ATL)United States
-
Deepa JagadeeshRecruitingAngioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Adult T-cell Leukemia/Lymphoma | Enteropathy Associated T-cell Lymphoma | Hepato-splenic T-cell Lymphoma | NK T-cell LymphomaUnited States
-
Samsung Medical CenterNational Cancer Center, Korea; Asan Medical Center; Yonsei University; Korea Cancer...CompletedCutaneous T Cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-negative | Angioimmunoblastic T Cell Lymphoma | Peripheral T Cell Lymphoma UnspecifiedKorea, Republic of
-
University of NebraskaNational Cancer Institute (NCI); AmgenCompletedPeripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Recurrent Adult T-cell Leukemia/LymphomaUnited States
-
Washington University School of MedicineWugen, Inc.RecruitingAcute Myeloid Leukemia | Sezary Syndrome | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult T Cell Leukemia | Adult T Cell Lymphoma | Hepatosplenic T-cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Enteropathy-Associated T-Cell Lymphoma | T-Cell Non-Hodgkin... and other conditionsUnited States
-
Karyopharm Therapeutics IncTerminatedCutaneous T-cell Lymphoma (CTCL) | Peripheral T-cell Lymphoma (PTCL)Australia, Singapore
-
SciTech Development, LLCRush University Medical CenterRecruitingMycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditionsUnited States
Clinical Trials on endostar and CHOP
-
Japan Clinical Oncology GroupMinistry of Health, Labour and Welfare, JapanTerminatedNon-Hodgkin's LymphomaJapan
-
Emergent BioSolutionsTerminated
-
Yune ZhaoUnknownHard Nuclear Cataract | Corneal Endothelial Cell | Progressive Cracking TechniqueChina
-
Sherief Abd-ElsalamRecruiting
-
Sun Yat-sen UniversityCompletedDiffuse Large B-cell Lymphoma
-
Ruijin HospitalActive, not recruitingPeripheral T-cell LymphomaChina
-
Affiliated Hospital of North Sichuan Medical CollegeJiangsu Simcere Pharmaceutical Co., Ltd.Unknown
-
Nanjing Yoko Biomedical Co., Ltd.RecruitingDiffuse Large B-Cell Lymphoma, Unspecified SiteChina
-
Eastern Hepatobiliary Surgery HospitalCompletedHepatocellular Carcinoma | Portal Vein Tumor ThrombusChina
-
The University of Texas Health Science Center at...Withdrawn